Department of Health Sciences (DISSAL), University of Genoa.
Clinica Malattie Infettive, San Martino Policlinico Hospital - IRCCS for Oncology and Neurosciences, Genoa, Italy.
Curr Opin Infect Dis. 2021 Dec 1;34(6):701-709. doi: 10.1097/QCO.0000000000000757.
To discuss the current literature on novel agents for the treatment of carbapenem-resistant nonfermenting Gram-negative bacteria (NF-GNB) infections.
Some novel agents have recently become available that are expected to replace classical polymyxins as the first-line options for the treatment of carbapenem-resistant NF-GNB infections.
In this narrative review, we provide a brief overview of the differential activity of various recently approved agents against NF-GNB most encountered in the daily clinical practice, as well as the results from phase-3 randomized clinical trials and large postapproval observational studies, with special focus on NF-GNB. Since resistance to novel agents has already been reported, the use of novel agents needs to be optimized, based on their differential activity (not only in terms of targeted bacteria, but also of resistance determinants), the local microbiological epidemiology, and the most updated pharmacokinetic/pharmacodynamic data. Large real-life experiences remain of crucial importance for further refining the optimal treatment of NF-GNB infections in the daily clinical practice.
讨论治疗耐碳青霉烯非发酵革兰阴性菌（NF-GNB）感染的新型药物的当前文献。
一些新型药物最近已上市，有望取代经典的多黏菌素，成为治疗耐碳青霉烯 NF-GNB 感染的一线选择。
在这篇叙述性综述中，我们简要概述了最近批准的各种药物对日常临床实践中最常遇到的 NF-GNB 的不同活性，以及 3 期随机临床试验和大型上市后观察性研究的结果，特别关注 NF-GNB。由于已经报道了对新型药物的耐药性，因此需要根据其不同的活性（不仅针对目标细菌，还针对耐药决定因素）、当地微生物流行病学和最新的药代动力学/药效学数据来优化新型药物的使用。大型真实世界的经验对于进一步完善 NF-GNB 感染在日常临床实践中的最佳治疗方案仍然至关重要。
